연구동향 분석

Uterine Malignant Mixed Müllerian Tumors Following Treatment with Selective Estrogen Receptor Modulators in Patients with Breast Cancer: A Report of 13 Cases and Their Clinicopathologic Characteristics

정병관 성창옥 김규래 2019년

논문상세정보
인용/피인용
' Uterine Malignant Mixed Müllerian Tumors Following Treatment with Selective Estrogen Receptor Modulators in Patients with Breast Cancer: A Report of 13 Cases and Their Clinicopathologic Characteristics' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Breast neoplasm
  • Malignant Müllerian mixed tumor
  • Tamoxifen
  • p53
  • selectiveestrogenreceptormodulators
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
223 0

0.0%

' Uterine Malignant Mixed Müllerian Tumors Following Treatment with Selective Estrogen Receptor Modulators in Patients with Breast Cancer: A Report of 13 Cases and Their Clinicopathologic Characteristics' 의 참고문헌

  • Uterine sarcoma associated with tamoxifen use
    Wysowski DK [2002]
  • Uterine carcinosarcomas in patients receiving tamoxifen : a report of 19 cases
  • Uterine carcinosarcoma/malignant mixed Müllerian tumor incidence is increased in women with breast cancer, but independent of hormone therapy
  • The risk of developing uterine sarcoma after tamoxifen use
    Lavie O [2008]
  • The effect of tamoxifen on the endometrium
    Barakat RR [1995]
  • Tamoxifen treatment for breast cancer and risk of endometrial cancer : a case-control study
    Swerdlow AJ [2005]
  • Tamoxifen therapy for breast cancer and endometrial cancer risk
    Bernstein L [1999]
  • Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Mullerian tumor and sarcoma : a report of 8 cases and review of the literature
  • Tamoxifen activation of the estrogen receptor/AP-1 pathway : potential origin for the cellspecific estrogen-like effects of antiestrogens
    Webb P [1995]
  • Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer
    Curtis RE [2004]
  • Risk of endometrial cancer after tamoxifen treatment of breast cancer
  • Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen
    Bergman L [2000]
  • Reproductive factors, heterogeneity, and breast tumor subtypes in women of mexican descent
    Martinez ME [2013]
  • Primary ovarian small cell carcinoma of pulmonary type with coexisting endometrial carcinoma in a breast cancer patient receiving tamoxifen: a case report and literature review
    Yin L [2018]
  • Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers
    Cook LS [1995]
  • Pathology of endometrium treated with tamoxifen
    Ismail SM [1994]
  • Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure : comparison between tamoxifen-treated and nontreated breast cancer patients
    Cohen I [1999]
  • Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy:a case report and review of the literature
    Cohen I [1994]
  • Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer
    Shushan A [1996]
  • Oestrogen receptors in breast tumours : associations with age, menopausal status and epidemiological and clinical features in 735 patients
    Elwood JM [1980]
  • Long-acting luteinizing hormone-releasing hormone agonist for ovarian hyperstimulation induced by tamoxifen for breast cancer
    Kojima N [2018]
  • Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53mutations in ovarian carcinoma : an immunohistochemical and nucleotide sequencing analysis
  • Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells
    Pandey V [2017]
  • Hormone therapy for advanced breast cancer
    Kennedy BJ [1965]
  • High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma
  • Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women : a case-case study
    Song N [2014]
  • Gynecologic effects of tamoxifen and the association with endometrial carcinoma
    Assikis VJ [1995]
  • Endometrial stromal sarcoma development after hysterectomy and tamoxifen therapy
  • Endometrial cancer survival after breast cancer in relation to tamoxifen treatment : pooled results from three countries
    Jones ME [2012]
  • Endometrial cancer in tamoxifen-treated breast cancer patients : findings from the National Surgical Adjuvant Breast and Bowel Project(NSABP)B-14
    Fisher B [1994]
  • Endolymphatic stromal myosis associated with tamoxifen use
    Eddy GL [1997]
  • ERbeta decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function
    Bado I [2016]
  • Committee Opinion No. 601: Tamoxifen and uterine cancer
    [2014]
  • BRCA1, TP53, and CHEK2germline mutations in uterine serous carcinoma
  • Association of tamoxifen and uterine sarcoma
  • Association of 11beta hydroxysteroid dehydrogenase type I expression and activity with estrogen receptor beta in adipose tissue from postmenopausal women
    McInnes KJ [2012]
  • A CUE hints at tumor resistance
    Thomas C [2011]